Gabather
Sweden - SödertäljePharmaceutical
Focus: Gabather is a Swedish pharmaceutical company founded in 2014, focused on developing treatments in psychiatry, including anti-psychotics, anti-depressants/anxiolytics, and analgesics. The company is publicly traded but operates at a modest scale with limited disclosed operational metrics.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Gabather
AI assessmentNot HiringNo open roles listed right now. Follow Gabather to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
GT-002
Safety and TolerabilityClinical Trials (1)
NCT03817346Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
Phase 1Help build intelligence for Gabather
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.